Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes

ClinicalTrials.gov ID: NCT04982575

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04982575. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 9:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy and Safety of Co-administration of Cagrilintide s.c. 2.4 mg and Semaglutide s.c. 2.4 mg Once Weekly in Subjects With Type 2 Diabetes

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study looks at how well a new medicine called cagrilintide works together with semaglutide on blood sugar levels in people with type 2 diabetes compared to cagrilintide alone or semaglutide alone. Before a new medicine can be prescribed to people it needs to be tested to see if it is safe and effective. Participants will either get cagrilintide and semaglutide together or cagrilintide and a dummy medicine or semaglutide and a dummy medicine. Which treatment participants get is decided by chance. A dummy medicine (placebo) looks like the study medicine but does not contain any active medicine. The dummy medicine is in the study to see if the study medicine works as expected. Participants will get 2 injections per week on the same day. Participants will take the study medicine with a pen. A pen is a medical tool with a needle used for injections under the skin. The study doctor or staff will show how. The study will last for about 39 weeks. Participants will have 12 visits at the clinic and 5 phone calls with the study doctor. At 6 of the clinic visits participants must not eat and drink for 8 hours before the visit (water is allowed). Women who can become pregnant cannot take part in this study. Only women that are surgically sterilised or post-menopausal are allowed to participate in this study Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period

Study identification

NCT ID
NCT04982575
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
92 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 2, 2021 (Actual)
Primary completion
Jul 7, 2022 (Actual)
Completion
Jul 7, 2022 (Actual)
Last update posted
Dec 23, 2025

2021 – 2022

United States locations

U.S. sites
23
U.S. states
14
U.S. cities
22
Facility City State ZIP Site status
Uni of Alabama at Birmingham Birmingham Alabama 35233 —
Valley Research Fresno California 93720 —
Pacific Clinical Studies Los Alamitos California 90720 —
Velocity Clin Res Los Angeles Los Angeles California 90017 —
Encompass Clinical Research_Spring Valley Spring Valley California 91978 —
New West Physicians,Inc. Golden Colorado 80401 —
FPA Clinical Research Kissimmee Florida 34741 —
Florida Inst For Clin Res Orlando Florida 32825 —
Clinical Trial Res Assoc,Inc Plantation Florida 33324 —
Ellipsis Group Alpharetta Georgia 30022 —
East West Med Res Inst Honolulu Hawaii 96814 —
Macoupin Research Group Gillespie Illinois 62033 —
MD Medical Research Oxon Hill Maryland 20745 —
PharmQuest Life Sciences LLC Greensboro North Carolina 27408 —
Accellacare Wilmington North Carolina 28401 —
Lillestol Research LLC Fargo North Dakota 58104 —
Plains Clinical Research Center, LLC_Fargo Fargo North Dakota 58104 —
Holston Medical Group Kingsport Tennessee 37660 —
Velocity Clinical Res-Dallas Dallas Texas 75230 —
PlanIt Research, PLLC Houston Texas 77079 —
DCOL Ctr for Clin Res Longview Texas 75605 —
Selma Medical Associates Winchester Virginia 22601-3834 —
Capital Clin Res Ctr,LLC Olympia Washington 98502 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04982575, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 23, 2025 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.